Paramount is that despite the blocking of their activating receptors, the MACS-enriched NK cells expressing CD19, CD33, or CD123 CARs still exhibit highly specific cytotoxic activity against ALL and AML cells in vitro. Here, CD33 is linked to acute myeloid leukemia.